Patent · US Active

Compounds and compositions for the treatment of ocular disorders

US9956302B2 · kind B2 · utility

1Cited by
22References
50Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 12, 2017
Grant dateMay 1, 2018
Priority date
Expiry dateOct 12, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07C2601/08
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.